As we saw the beneficial effects of targeting Mfap4 in liver repopulation as well as in the very aggressive TAA model, we went on to test the impact of Mfap4 knockdown in a physiological mouse model of NAFLD. This evidence concerns the gene MFAP4 and metabolic dysfunction-associated steatotic liver disease.